Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
National Institutes of Health
Description
The Blueprint Neurotherapeutics Network (BPN) is a program that helps neuroscience researchers develop small molecule drugs for neurological conditions, taking them through the discovery and development phases up to clinical testing. Participants work with NIH-funded experts and organizations on different aspects like medicinal chemistry, pharmacokinetics, and toxicology. Projects can start at different stages with the aim of refining compounds and progressing candidates towards clinical tri…
The Blueprint Neurotherapeutics Network (BPN) supports neuroscience investigators in advancing small molecule drug discovery and development projects into clinical stages. Participants conduct disease-specific research and collaborate with NIH-funded consultants and contract research organizatio…
Source
Grant ID
PAR-24-063
Agency
National Institutes of Health
Subcategory/Subagency
National Institute of Neurological Disorders and Stroke
Program
SBIR
Key Dates
Opportunity Released
November 1, 2023
Open for Submission
November 1, 2023
Submission Deadline
August 18, 2026
Application Window Closes
August 18, 2026
Eligibility
The following categories of applicants are invited to apply:
- U.S. Small Business Concerns (SBCs) – for‑profit businesses with a U.S. place of business and not more than 500 employees (including affiliates)
- Joint ventures that qualify as U.S. Small Business Concerns (each party must meet SBIR/STTR ownership criteria; <50% participation by foreign business entities in the JV)
- U.S. small businesses owned and controlled (>50%) by one or more U.S. citizens or permanent resident aliens, or by other qualifying U.S.-owned business concerns
- U.S. small businesses owned by an Indian tribe, Alaska Native Corporation (ANC), or Native Hawaiian Organization (NHO) (or wholly owned business entities of such) as defined by SBA
- SBIR applicants only: U.S. small businesses that are >50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination thereof (subject to SBA rules; no single VC/HF/PE may own >50% unless itself a qualifying small business)
Similar opportunities
- Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
National Institutes of Health
- Innovation Grants to Nurture Initial Translational Efforts (IGNITE)
National Institutes of Health
- Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics): Biologics-based Therapy Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
National Institutes of Health
- Limited Competition: Renewal Applications for NINDS-supported Clinical Trial Cooperative Agreement Awards (U01)
National Institutes of Health
- Blueprint Neurotherapeutics Network for Biologics (BPN Biologics)
National Institutes of Health